Albumin Market by Source (Animal Sources, Plant Sources), Type (Non-Recombinant, Recombinant), Application, End User - Global Forecast 2024-2030

Albumin Market by Source (Animal Sources, Plant Sources), Type (Non-Recombinant, Recombinant), Application, End User - Global Forecast 2024-2030

The Albumin Market size was estimated at USD 6.53 billion in 2023 and expected to reach USD 6.94 billion in 2024, at a CAGR 6.61% to reach USD 10.23 billion by 2030.

Albumin is a complex and versatile protein that constitutes approximately 50%-60% of the total protein content in human blood plasma. It is synthesized predominantly by the liver and plays an essential role in physiological functions, such as maintaining osmotic pressure, binding and transporting various molecules, and acting as an antioxidant. Albumin's importance lies in its multifaceted contributions to overall health and well-being, making it a significant biomarker for assessing an individual's disease risk and clinical status. The growing usage of albumin in clinical settings for the treatment of burns and the rising prevalence of liver diseases where patients require a regular supply of HSA to maintain proper health functions has accelerated the use of albumin worldwide. However, risks associated with contamination and transmission of infectious agents in HSA products sourced from pooled human plasma donations impact albumin usage. Stringent regulatory guidelines for product approvals in different regions also affect the commercialization of albumin. Market players are investing in research and development initiatives that explore innovative production methods, such as plant-based expression systems or microbial fermentation processes capable of yielding high-quality albumin products at lower costs. New opportunities are emerging with the evolution of biotechnological advancements that enable the production of recombinant human albumins (rHA) through genetic engineering techniques.

Regional Insights

The Americas albumin market is advancing, driven by investments by pharmaceutical companies investing heavily in research and technology to develop advanced albumin formulations. Regulatory bodies such as the Food and Drug Administration (FDA) in the U.S. enforce strict quality control measures to assure safety standards of albumin. The FDA has also given approval for certain albumin products in recent years. Technological advancements such as recombinant HSA production are being researched across the U.S. and Canada to potentially reduce dependency on human plasma donations for albumin supply. The Asian albumin market is experiencing rapid expansion fueled by increasing healthcare expenditure and improving medical infrastructure in emerging countries demanding plasma-derived products for therapeutic purposes, including liver disease treatment, surgeries, and intensive care support. Europe is a potential contributor to the global albumin market, with an established consumption base and robust manufacturing capabilities. The use of albumin in Europe is primarily focused on critical care applications such as sepsis management, volume replacement therapies, and therapeutic plasma exchange procedures. The European Medicines Agency (EMA) regulates the production and distribution of albumin within the European Union (EU).

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the Albumin Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • Incidence of chronic diseases and use of albumin as a predictor of postoperative surgical site infections
    • Surging utilization of albumin as a food and cosmetic ingredient
    • Market Restraints
      • Potential of albumin to cause transmission of infections
      • Market Opportunities
        • Ongoing research activities regarding albumin nanoparticles
        • Advancements in albumin production and purification methods
        • Market Challenges
          • Stringent regulations associated with albumin manufacturing and quality control
          • Market Segmentation Analysis
            • Source: Consumer shift toward the plant-based albumins due to enhanced sustainability for specific therapeutic purposes.
            • Type: Enhanced emphasis on the research and development of recombinant albumin as a synthetic protein to promote recombinant DNA technology
            • Application: Rising focus on vaccine manufacturing and drug delivery applications
            • End-User: Extensive end-users of the albumin in hospitals and blood banks
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Albumin Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Albumin Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • Grifols Completes Enrollment In Phase 3 Study Of Long-Term Albutein (Albumin-Human Injection) Therapy For Patients With Decompensated Cirrhosis
              
              Grifols SA has completed enrollment in the PRECIOSA Phase 3 trial, which aims to evaluate the potential of long-term albumin treatment with Albutein in increasing the survival time of patients with decompensated cirrhosis and ascites. Albumin exhibits antioxidant and anti-inflammatory properties that could help alleviate complications associated with decompensated cirrhosis, ultimately reducing mortality rates for this condition.
              
              Kedrion's Global Portfolio Expands To China To Supply Human Albumin
              
              Kedrion Biopharma, an international biopharmaceutical company, announced the approval of its human Albumin product for release in the Chinese market. This approval is a significant milestone for the company, as it marks the first-ever biopharmaceutical product to be approved in China. It enables Kedrion to regularly ship its products to the country, meeting the substantial demand from China.
              
              GC Biopharma inks USD 90mn deal for blood products in Brazil
              
              GC Biopharma Co. has entered into a five-year supply agreement with Blau Farmacêutica, a Brazilian pharmaceutical company, to provide its IVIG-SN 5% blood product, valued at USD 90.48 million. This partnership with Blau Farmacêutica represents a significant opportunity for GC Biopharma to expand its global market share and further contribute to the healthcare industry.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Albumin Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the Albumin Market, highlighting leading vendors and their innovative profiles. These include Aadi Bioscience, Inc., Agilent Technologies, Inc., Akron Biotech, Atlantis Bioscience Pte Ltd., Avantor Inc., Baxter International Inc., Becton, Dickinson and Company, Bio Products Laboratory Ltd., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biogenix Inc. Pvt. Ltd., Biophyll GmbH, Biorbyt Ltd., Biowest SAS, Boston BioProducts Inc., Bristol-Myers Squibb Company, CENTURION PHARMA İlaç Sanayi ve Ticaret A.Ş., China Biologic Products Holdings, Inc. by Taibang Biologic Group, CSL Limited, Dem İlaç, F. Hoffmann-La Roche AG, GC Biopharma Corp., Glentham Life Sciences Limited, Grifols SA, InVitria, InVitroCare Inc., Kedrion S.p.A, Kraeber & Co. GmbH, Lazuline Biotech Private Limited, LGC Science Group Holdings Limited, Merck KGaA, Midas Pharma GmbH, Octapharma AG, Promega Corporation, Prospec-Tany Technogene Ltd., Rockland Immunochemicals Inc., Rocky Mountain Biologicals, LLC, Sartorius AG, Serion GmbH, SK Plasma, Takeda Pharmaceuticals Company Limited, Thermo Fisher Scientific Inc., Ventria Bioscience Inc., and VitroScient.
            
            Market Segmentation & Coverage
            
            This research report categorizes the Albumin Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Source
              • Animal Sources
                • Bovine Serum Albumin
                • Human Serum Albumin
                • Ovalbumin
                • Plant Sources
                • Type
                  • Non-Recombinant
                  • Recombinant
                  • Application
                    • Cosmetic Ingredient
                    • Culture Media
                    • Drug Delivery
                    • Food Ingredient
                    • Therapeutic
                    • Vaccine Ingredient
                    • End User
                      • Pharmaceutical & Biotechnology
                      • Research Institutes
                      • Region
                        • Americas
                          • Argentina
                          • Brazil
                          • Canada
                          • Mexico
                          • United States
                            • California
                            • Florida
                            • Illinois
                            • New York
                            • Ohio
                            • Pennsylvania
                            • Texas
                            • Asia-Pacific
                              • Australia
                              • China
                              • India
                              • Indonesia
                              • Japan
                              • Malaysia
                              • Philippines
                              • Singapore
                              • South Korea
                              • Taiwan
                              • Thailand
                              • Vietnam
                              • Europe, Middle East & Africa
                                • Denmark
                                • Egypt
                                • Finland
                                • France
                                • Germany
                                • Israel
                                • Italy
                                • Netherlands
                                • Nigeria
                                • Norway
                                • Poland
                                • Qatar
                                • Russia
                                • Saudi Arabia
                                • South Africa
                                • Spain
                                • Sweden
                                • Switzerland
                                • Turkey
                                • United Arab Emirates
                                • United Kingdom
                                
                                
                                Please Note: PDF & Excel + Online Access - 1 Year